Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 7/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.79 |
| ▸ | LMNA | P02545 | 5/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.79 |
| ▸ | NR3C1 | P04150 | 7/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.73 |
| ▸ | PGR | P06401 | 4/20 | 0.73 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.73 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.73 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.73 |
| ▸ | BLM | P54132 | 1/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.73 |
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | AR | P10275 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | APEX1 | P27695 | 1/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL94367 | 1.00 | HIF1A (0.79) | HIF1ACYP3A4LMNAALDH1A1NR3C1 | |
| SCHEMBL9654452 | 1.00 | HIF1A (0.79) | HIF1ACYP3A4LMNAALDH1A1NR3C1 | |
| SCHEMBL17884670 | 1.00 | HIF1A (0.79) | HIF1ACYP3A4LMNAALDH1A1NR3C1 | |
| SCHEMBL13657566 | 1.00 | HIF1A (0.79) | HIF1ACYP3A4LMNAALDH1A1NR3C1 | |
| SCHEMBL17665286 | 1.00 | HIF1A (0.79) | HIF1ACYP3A4LMNAALDH1A1NR3C1 | |
| SCHEMBL3764416 | 1.00 | HIF1A (0.79) | HIF1ACYP3A4LMNAALDH1A1NR3C1 | |
| SCHEMBL19715951 | 1.00 | HIF1A (0.79) | HIF1ACYP3A4LMNAALDH1A1NR3C1 | |
| SCHEMBL11856116 | 0.92 | HIF1A (0.79) | HIF1ACYP3A4LMNAALDH1A1NR3C1 | |
| SCHEMBL11856120 | 0.92 | HIF1A (0.79) | HIF1ACYP3A4LMNAALDH1A1NR3C1 | |
| SCHEMBL11845795 | 0.91 | CYP3A4 (0.77) | HIF1ACYP3A4LMNAALDH1A1NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110612119-A | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | 西雅图儿童医院（DBA西雅图儿童研究所） | 2019-12-24 | — | — | CN | claimed |
| US-20190000862-A1 | METHODS AND SYSTEMS FOR THE DELIVERY OF A THERAPEUTIC AGENT | HANANJA EHF (IS) | 2019-01-03 | — | — | US | claimed |
| WO-2018148224-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) | 2018-08-16 | — | — | WO | claimed |
| US-20080038219-A1 | Novel Composition for a Topical Skin Treatment Base and Medicated Applications Thereof | CALGENEX CORPORATION (US) | 2008-02-14 | — | — | US | claimed |
| US-20070184114-A1 | Formulation for topical non-invasive application in vivo | IDEA AG (DE) | 2007-08-09 | — | — | US | claimed |
| US-7175850-B2 | Formulation for topical non-invasive application in vivo | IDEA AG (DE) | 2007-02-13 | — | — | US | claimed |
| EP-1140021-B1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG (DE) | 2004-08-04 | — | — | EP | claimed |
| JP-2002533379-A | — | — | 2002-10-08 | — | — | JP | claimed |
| US-20020064524-A1 | Formulation for topical non-invasive application in vivo | IDEA AG (DE) | 2002-05-30 | — | — | US | claimed |
| EP-1140021-A1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG (DE) | 2001-10-10 | — | — | EP | claimed |
| WO-2000038653-A1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG. (DE) | 2000-07-06 | — | — | WO | claimed |
| EP-0186948-B1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF 17ALPHA-HYDROXYPROGESTERONES AND CORTICOIDS FROM AN ENOL STEROID | THE UPJOHN COMPANY (US) | 1989-01-25 | — | — | EP | claimed |
| EP-0186948-A1 | Process and intermediates for the preparation of 17alpha-hydroxyprogesterones and corticoids from an enol steroid | THE UPJOHN COMPANY (US) | 1986-07-09 | — | — | EP | claimed |
| US-20240226160-A9 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240210288-A1 | Representative Diagnostics | VENTANA MED SYST INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240131072-A1 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-04-25 | — | — | US | disclosed |
| US-4181669-A | A CARBODIIMIDE WITH ACID CATALYSTS AS A CONDENSATION AGENT | AKTIEBOLAGET LEO (SE) | 1980-01-01 | — | — | US | disclosed |
| US-4180504-A | Method for the preparation of esters | AKTIEBOLAGET LEO (SE) | 1979-12-25 | — | — | US | disclosed |
| US-4036831-A | Trimethyl siloxane steroid intermediates | STEROID DEVELOPMENT COMPANY ESTABLISHMENT (CH) | 1977-07-19 | — | — | US | disclosed |
| US-3984544-A | Retinoic acid esters of steroids of the pregnane series, their use in the treatment of acne and pharmaceutical formulations useful therefor | SCHERING CORPORATION (US) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190000862-A1 | METHODS AND SYSTEMS FOR THE DELIVERY OF A THERAPEUTIC AGENT | TMEM205, NUP205, PIGS | HIF1A 428/4885CYP3A4 4715/4885LMNA 458/4885 |
| US-20020064524-A1 | Formulation for topical non-invasive application in vivo | CUTA, LPO, GPX4 | HIF1A 2297/4885CYP3A4 1398/4885LMNA 3910/4885 |
| US-20070184114-A1 | Formulation for topical non-invasive application in vivo | GPX4, LPO, MMP8 | HIF1A 2483/4885CYP3A4 950/4885LMNA 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.